Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sabirnetug IV vs SC in Healthy Participants
NCT06511570Phase 1Completed
- Sponsor
- Acumen Pharmaceuticals, Inc.
- Start
- Jun 2024
- Primary completion
- Sep 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of sabirnetug in Alzheimer's disease (AD) (2 arms), sponsored by Acumen Pharmaceuticals, Inc. Primary endpoints: Blood levels of sabirnetug (ACU193), Time to reach maximum blood levels of sabirnetug and 6 more. Started Jun 2024; status: completed.
02
Drugs
sabirnetug
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06511570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06511570.